VNDA insider trading
NasdaqGM HealthcareVanda Pharmaceuticals Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Company website: www.vandapharma.com
VNDA insider activity at a glance
FilingIQ has scored 354 insider transactions for VNDA since Apr 20, 2015. The most recent filing in our index is dated Apr 22, 2026.
Across the full history, 36 open-market purchases
and 155 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VNDA insider trades is 58.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VNDA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for VNDA?
- FilingIQ tracks 354 Form 4 insider transactions for VNDA (Vanda Pharmaceuticals Inc.), covering filings from Apr 20, 2015 onwards. 12 of those were filed in the last 90 days.
- Are VNDA insiders net buyers or net sellers?
- Across the full Form 4 history for VNDA, 36 transactions (10%) were open-market purchases and 155 (44%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VNDA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is VNDA in?
- Vanda Pharmaceuticals Inc. (VNDA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $359.38M.
Methodology & sources
Every VNDA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.